Trial Profile
Phase II Study of Buparlisib in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Aug 2023
Price :
$35
*
At a glance
- Drugs Buparlisib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 25 Nov 2019 Status changed from active, no longer recruiting to completed.
- 27 May 2019 Planned End Date changed from 1 Jun 2019 to 1 Aug 2019.
- 14 Jan 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Jun 2019.